Immunotherapy resistance may stem from an unexpected metabolic partnership between dying tumor cells and the immune system's own regulatory machinery. While oncologists have long observed that some patients fail to respond to checkpoint inhibitors, the cellular mechanisms underlying this resistance have remained elusive, particularly in metabolically hostile tumor environments.
New spatial analysis of human liver tumors reveals that regulatory T cells (Tregs) exploit ammonia waste from tumor metabolism through a sophisticated two-pathway system. These immunosuppressive cells upregulate argininosuccinate lyase to detoxify ammonia via the urea cycle, while simultaneously converting ammonia into spermine through FOXP3-regulated spermine synthase. Crystallographic studies demonstrate that spermine directly binds PPARγ, triggering enhanced mitochondrial oxidative phosphorylation that amplifies Treg immunosuppressive capacity. Meanwhile, effector T cells die in these same ammonia-rich tumor regions, creating sanctuaries where cancer cells evade immune destruction.
This metabolic reprogramming represents a critical vulnerability in current immunotherapy approaches. Anti-PD-1 treatment paradoxically worsens the problem by causing tumor cell death that releases additional ammonia through transdeamination, further strengthening Treg function. The finding explains why some tumors become more immunosuppressive following checkpoint blockade therapy. Unlike previous research focused on glucose or lipid metabolism in cancer immunity, this work identifies ammonia as a previously unrecognized metabolic currency that tumors use to corrupt immune surveillance. The discovery suggests therapeutic strategies targeting ammonia production or spermine synthesis could restore anti-tumor immunity where conventional immunotherapies fail.